Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology-Reference-Cited by-同舟云学术

Pyrimidinone Nicotinamide Mimetics as Selective Tankyrase and Wnt Pathway Inhibitors Suitable for in Vivo Pharmacology

Published:2015-01-17 Issue:3 Volume:6 Page:254-259
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Johannes Jeffrey W.¹,Almeida Lynsie¹,Barlaam Bernard²,Boriack-Sjodin P. Ann¹,Casella Robert¹,Croft Rosemary A.²,Dishington Allan P.²,Gingipalli Lakshmaiah¹,Gu Chungang¹,Hawkins Janet L.²,Holmes Jane L.²,Howard Tina²,Huang Jian¹,Ioannidis Stephanos¹,Kazmirski Steven¹,Lamb Michelle L.¹,McGuire Thomas M.²,Moore Jane E.²,Ogg Derek²,Patel Anil²,Pike Kurt G.²,Pontz Timothy¹,Robb Graeme R.²,Su Nancy¹,Wang Haiyun¹,Wu Xiaoyun¹,Zhang Hai-Jun¹,Zhang Yue¹,Zheng Xiaolan¹,Wang Tao¹

Affiliation:

1. AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

2. AstraZeneca R&D Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ml5003663

Reference21 articles.

1. WNT signalling pathways as therapeutic targets in cancer

2. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium